Leveraging an RNA-targeting platform for the discovery of cell-active c-MYC mRNA-binding small molecules

Ribometrix has identified a druggable RNA element within the oncogene c‑MYC and deployed its RNA-targeted drug discovery platform to develop novel cell-active MYC‑reducing compounds. These compounds engage cellular c‑MYC mRNA and lead to a selective reduction of c‑MYC protein as well as direct downstream biomarkers. Ribometrix is unlocking the ability to target c‑MYC, with the potential to address a broad range of oncology indications.